Immune thrombocytopenia

119,570views

Immune thrombocytopenia

Watch later

Watch later

Complications during pregnancy: Pathology review
Essential thrombocythemia (NORD)
Nucleotide metabolism
Gout
Antigout medications
Microcytic anemia: Pathology review
Macrocytic anemia: Pathology review
Non-hemolytic normocytic anemia: Pathology review
Extrinsic hemolytic normocytic anemia: Pathology review
Anemia of chronic disease
Intrinsic hemolytic normocytic anemia: Pathology review
T-cell development
Immunodeficiencies: Clinical
Non-Hodgkin lymphoma
Plasma cell disorders: Pathology review
Complement system
Immunodeficiencies: Phagocyte and complement dysfunction: Pathology review
Selective immunoglobulin A deficiency
X-linked agammaglobulinemia
Hyper IgM syndrome
DiGeorge syndrome
Immunodeficiencies: Combined T-cell and B-cell disorders: Pathology review
Purine and pyrimidine synthesis and metabolism disorders: Pathology review
Severe combined immunodeficiency
Ataxia-telangiectasia
Wiskott-Aldrich syndrome
Leukocyte adhesion deficiency
Chronic granulomatous disease
Chediak-Higashi syndrome
Herpes simplex virus
Varicella zoster virus
Epstein-Barr virus (Infectious mononucleosis)
Guillain-Barre syndrome
Cytomegalovirus
Cytomegalovirus infection after transplant (NORD)
Congenital cytomegalovirus (NORD)
MHC class I and MHC class II molecules
Leukemias: Pathology review
Leukemia: Clinical
Thrombotic thrombocytopenic purpura
Immune thrombocytopenia
Thrombocytopenia: Clinical
Platelet disorders: Pathology review
Blood products and transfusion: Clinical
Heparin-induced thrombocytopenia
Myeloproliferative disorders: Pathology review
Myeloproliferative neoplasms: Clinical
Myelofibrosis (NORD)
Aplastic anemia
Sideroblastic anemia
Fanconi anemia
Hodgkin lymphoma
Lymphoma: Clinical
Lymphomas: Pathology review
Monoclonal gammopathy of undetermined significance
Plasma cell disorders: Clinical
Multiple myeloma
Waldenstrom macroglobulinemia
Oncogenes and tumor suppressor genes
Vaccinations
Vaccinations: Clinical
Renal system anatomy and physiology
Development of the renal system
Action potentials in myocytes
Calcium channel blockers

Flashcards

Immune thrombocytopenia

0 of 13 complete

Questions

USMLE® Step 1 style questions USMLE

0 of 2 complete

A 42-year-old female comes to the clinic complaining of gingival bleeding and dark purple spots on her legs. The patient first noticed the dark spots on her legs 2 months ago, but the gingival bleeding started 5 days ago. Past history is notable for intravenous drug use and hepatitis C infection. Temperature is 37.0°C (98.6°F), pulse is 78/min, respirations are 12/min, and blood pressure is 128/76 mmHg. Examination of the patient’s oropharynx and gingiva reveals petechiae with pinpoint bleeding. Cardiac, pulmonary, and abdominal exams are noncontributory. Purpura are observed on the bilateral legs. Laboratory testing is obtained, and the results are shown below.  
 
 Laboratory value   Result  Reference Range 
 Platelet count  25,000/mm3   150,000-400,000/mm3 
 Hemoglobin (Hb)  13.5 g/dL  12-16 g/dL 
 Leukocyte count  11,000/mm3  4,500-11,000/mm3 
   
Which of the following serological findings would most likely be present in this patient? 

Transcript

Watch video only

Immune thrombocytopenic purpura or ITP is an autoimmune condition in which the body produces antibodies against its own thrombocytes or platelets, which are destroyed. And this result in purpura, or small bleeding spots beneath the skin.

Normally, when there’s any kind of damage to the blood vessel, hemostasis occurs, which is the process that stops the bleeding and plugs the damaged vessel to limit the blood loss.

And there are two steps: primary and secondary hemostasis. During primary hemostasis, platelets aggregate to form a plug at the site of an injured blood vessel.

Platelet aggregation is mediated by surface proteins found on platelets, called GP2B3A receptors. While these platelets are aggregating, secondary hemostasis kicks in.

Secondary hemostasis is also called coagulation, because that’s when clotting factors come into play one after another, with a view to cleaving fibrinogen into fibrin.

Then, fibrin forms a protein mesh, kinda like a giant net that covers the platelet plug and stabilizes it.

Now, in ITP, the spleen produces certain IgG autoantibodies which bind to the platelet receptor Gp2B3A, and target the platelet-antibody complexes for destruction in the spleen.

This leads to lowering of platelet counts in the blood, which makes it harder for bleeding to stop. Now, ITP can be acute or chronic.

Acute ITP usually affects children, a couple of weeks after a viral infection, and resolves spontaneously within two months.

Chronic ITP usually affect females of reproductive age, and persist more than six months. Chronic ITP can also be primary, when it occurs without an underlying trigger, or secondary, when it’s triggered by another condition like hepatitis C, HIV, or lupus.

Most of the time, ITP is asymptomatic. In some cases, it can cause purpura, which are red or purple spots on the skin, measuring 0.3 to 1 cm in diameter.

In severe cases of ITP, when platelet levels get very low, there may be frequent mucosal bleeding, which most commonly presents as epistaxis, meaning nose bleeds.

Sources

  1. "Robbins Basic Pathology" Elsevier (2017)
  2. "Pathophysiology of Disease: An Introduction to Clinical Medicine 8E" McGraw-Hill Education / Medical (2018)
  3. "Harrison's Principles of Internal Medicine" McGraw-Hill (2004)
  4. "Purpura thrombopénique immunologique [Immune thrombocytopenic purpura]" Rev Prat (2019)
  5. "Immune Thrombocytopenic Purpura" New England Journal of Medicine (2002)
  6. "[TREATMENT OF IMMUNE THROMBOCYTOPENIC PURPURA IN ADULTS: UPDATE]" Harefuah (2019)